HUE049393T2 - Biokémiailag stabilizált HIV-1 ENV trimer vakcina - Google Patents

Biokémiailag stabilizált HIV-1 ENV trimer vakcina

Info

Publication number
HUE049393T2
HUE049393T2 HUE18150843A HUE18150843A HUE049393T2 HU E049393 T2 HUE049393 T2 HU E049393T2 HU E18150843 A HUE18150843 A HU E18150843A HU E18150843 A HUE18150843 A HU E18150843A HU E049393 T2 HUE049393 T2 HU E049393T2
Authority
HU
Hungary
Prior art keywords
env trimer
stabilized hiv
vaccine
biochemically
biochemically stabilized
Prior art date
Application number
HUE18150843A
Other languages
English (en)
Inventor
Stephen C Harrison
Bing Chen
Dan H Barouch
Joseph P Nikolola
Michael Scott Seaman
Original Assignee
Childrens Medical Center
Beth Israel Deaconess Medical Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, Beth Israel Deaconess Medical Ct Inc filed Critical Childrens Medical Center
Publication of HUE049393T2 publication Critical patent/HUE049393T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect
HUE18150843A 2008-10-10 2009-10-13 Biokémiailag stabilizált HIV-1 ENV trimer vakcina HUE049393T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10444908P 2008-10-10 2008-10-10

Publications (1)

Publication Number Publication Date
HUE049393T2 true HUE049393T2 (hu) 2020-09-28

Family

ID=42101262

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE09820044A HUE037270T2 (hu) 2008-10-10 2009-10-13 Biokémiailag stabilizált HIV-1 ENV trimer vakcina
HUE18150843A HUE049393T2 (hu) 2008-10-10 2009-10-13 Biokémiailag stabilizált HIV-1 ENV trimer vakcina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE09820044A HUE037270T2 (hu) 2008-10-10 2009-10-13 Biokémiailag stabilizált HIV-1 ENV trimer vakcina

Country Status (14)

Country Link
US (6) US9707289B2 (hu)
EP (2) EP3335728B8 (hu)
AU (1) AU2009303284B2 (hu)
CY (2) CY1119921T1 (hu)
DK (2) DK3335728T3 (hu)
ES (2) ES2659875T3 (hu)
HR (2) HRP20180281T1 (hu)
HU (2) HUE037270T2 (hu)
LT (2) LT3335728T (hu)
PL (2) PL2340038T3 (hu)
PT (2) PT2340038T (hu)
SI (2) SI2340038T1 (hu)
TR (1) TR201802130T4 (hu)
WO (1) WO2010042942A2 (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110831A2 (en) 2005-04-12 2006-10-19 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
CA2683752A1 (en) 2007-04-13 2008-10-23 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20120070488A1 (en) * 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
SI2340038T1 (en) 2008-10-10 2018-05-31 Children's Medical Center Corporation A biochemically stabilized HIV-1 ENV TRIMER vaccine
EP2413951A4 (en) 2009-04-03 2015-05-20 Univ Duke FORMULATION FOR GENERATING A WIDE REACTIVE NEUTRALIZATION OF HIV ANTIBODIES
US9060984B2 (en) * 2010-10-30 2015-06-23 George Dacai Liu Recombinant HIV-1 envelope proteins comprising stabilizing two-cysteine mini-domains in gp41
WO2014022475A2 (en) * 2012-08-03 2014-02-06 Dana-Faber Cancer Institute, Inc. Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers
EA030983B1 (ru) 2013-01-07 2018-10-31 Бет Изрейэл Диконисс Медикал Сентер, Инк. ВАКЦИНЫ, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЕ ТРИМЕРЫ ОБОЛОЧКИ (Env) ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2014134547A1 (en) 2013-02-28 2014-09-04 Therabiol, Inc. Hiv antigens and antibodies
US9675687B2 (en) 2013-03-15 2017-06-13 University Of Massachusetts Compositions and methods to treat AIDS
US10076567B2 (en) 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof
WO2015051270A1 (en) 2013-10-04 2015-04-09 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same
US11116774B2 (en) 2014-07-11 2021-09-14 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
CN112121160A (zh) * 2014-09-26 2020-12-25 贝斯以色列护理医疗中心有限公司 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物
WO2016196471A1 (en) 2015-06-02 2016-12-08 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
EP3390430B1 (en) 2015-12-15 2019-08-28 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
CN109219448B (zh) 2016-06-16 2022-09-20 扬森疫苗与预防公司 Hiv疫苗配制品
US10307477B2 (en) 2016-09-02 2019-06-04 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US10793607B2 (en) 2016-09-15 2020-10-06 Janssen Vaccines & Prevention B.V. Trimer stabilizing HIV envelope protein mutations
US11230572B2 (en) 2016-10-17 2022-01-25 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same
KR20200015759A (ko) 2017-06-15 2020-02-12 얀센 백신스 앤드 프리벤션 비.브이. Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법
AU2018304502B2 (en) 2017-07-19 2022-03-31 Janssen Vaccines & Prevention B.V. Trimer stabilizing HIV envelope protein mutations
WO2019018724A1 (en) 2017-07-21 2019-01-24 Janssen Vaccines & Prevention B.V. METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS
WO2019055888A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT
CN112770770A (zh) 2018-09-25 2021-05-07 扬森疫苗与预防公司 共定位施用疫苗组分诱导针对人类免疫缺陷病毒的免疫应答的方法
WO2020237052A1 (en) 2019-05-22 2020-11-26 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
KR20220092896A (ko) 2019-11-07 2022-07-04 얀센 백신스 앤드 프리벤션 비.브이. 단백질 정제
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
CA2384271A1 (en) * 1999-09-17 2001-03-22 Joseph G. Sodroski Stabilized soluble glycoprotein trimers
WO2004044155A2 (en) 2002-11-07 2004-05-27 Beth Israel Deaconess Medical Center MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
US7901690B2 (en) * 2002-12-03 2011-03-08 University Of Massachusetts Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
WO2005052119A2 (en) 2003-11-19 2005-06-09 Beth Israel Deaconess Medical Center Adjuvants of immune response
US20080274134A1 (en) * 2004-06-15 2008-11-06 Norbert Schulke Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex
CA2573702C (en) * 2004-07-16 2013-10-15 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Vaccine constructs and combination of vaccines designed to improve the breadth of the immune response to diverse strains and clades of hiv
AU2005293568B2 (en) 2004-10-13 2010-10-28 Beth Israel Deaconess Medical Center Inc. Improved adenoviral vectors and uses thereof
WO2007005934A2 (en) * 2005-07-06 2007-01-11 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
CN101969996A (zh) 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
CA2655934A1 (en) 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Soluble stabilized trimeric hiv env proteins and uses thereof
CA2667358A1 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
SI2340038T1 (en) 2008-10-10 2018-05-31 Children's Medical Center Corporation A biochemically stabilized HIV-1 ENV TRIMER vaccine
DK2358757T3 (da) 2008-11-18 2019-01-02 Beth Israel Deaconess Medical Ct Inc Antivirale vacciner med forbedret cellulær immunogenicitet
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
PT3556396T (pt) 2010-08-31 2022-07-04 Scripps Research Inst Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
WO2013036791A2 (en) 2011-09-09 2013-03-14 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2766037A4 (en) 2011-10-12 2015-08-05 Scripps Research Inst HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF
WO2014047261A1 (en) 2012-09-19 2014-03-27 Beth Israel Deaconess Medical Center, Inc. Viruses associated with immunodeficiency and enteropathy and methods using same
JP2015536147A (ja) 2012-11-16 2015-12-21 ベス イスラエル デアコネス メディカル センター インコーポレイテッド 組換えアデノウイルスおよびその使用
EA030983B1 (ru) 2013-01-07 2018-10-31 Бет Изрейэл Диконисс Медикал Сентер, Инк. ВАКЦИНЫ, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЕ ТРИМЕРЫ ОБОЛОЧКИ (Env) ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN105518022B (zh) * 2013-07-08 2020-08-18 诺华股份有限公司 具有嵌合表面蛋白的轮状病毒颗粒
EP3052132B1 (en) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
US10444908B2 (en) 2016-12-31 2019-10-15 Innoventions, Inc. Virtual touchpads for wearable and portable devices

Also Published As

Publication number Publication date
LT2340038T (lt) 2018-04-10
ES2765890T3 (es) 2020-06-11
US10653770B2 (en) 2020-05-19
US10307478B2 (en) 2019-06-04
EP3335728B8 (en) 2020-03-11
TR201802130T4 (tr) 2018-03-21
HUE037270T2 (hu) 2018-08-28
US20200023056A1 (en) 2020-01-23
ES2659875T3 (es) 2018-03-19
LT3335728T (lt) 2020-03-10
AU2009303284A1 (en) 2010-04-15
WO2010042942A2 (en) 2010-04-15
EP3335728A1 (en) 2018-06-20
HRP20180281T1 (hr) 2018-05-04
EP3335728B1 (en) 2019-12-25
PT2340038T (pt) 2018-02-21
US20200323976A1 (en) 2020-10-15
US10463729B2 (en) 2019-11-05
SI2340038T1 (en) 2018-05-31
EP2340038B1 (en) 2018-01-10
DK2340038T3 (en) 2018-02-26
US20170290907A1 (en) 2017-10-12
SI3335728T1 (sl) 2020-04-30
EP2340038A2 (en) 2011-07-06
DK3335728T3 (da) 2020-02-24
US9950060B2 (en) 2018-04-24
AU2009303284B2 (en) 2016-01-28
US20180207259A1 (en) 2018-07-26
WO2010042942A3 (en) 2010-06-24
HRP20200370T1 (hr) 2020-06-12
PL2340038T3 (pl) 2018-07-31
CY1119921T1 (el) 2018-12-12
CY1122745T1 (el) 2021-01-27
PL3335728T3 (pl) 2020-06-29
US9707289B2 (en) 2017-07-18
US11229696B2 (en) 2022-01-25
US20190240319A1 (en) 2019-08-08
US20120045472A1 (en) 2012-02-23
PT3335728T (pt) 2020-02-19
EP2340038A4 (en) 2012-08-15

Similar Documents

Publication Publication Date Title
EP2340038A4 (en) BIOCHEMICALLY STABILIZED HIV-1 ENV TRIMER VACCINE
IL217008A0 (en) Vaccine
GB0810305D0 (en) Influenza vaccination
HRP20151124T1 (en) Vaccine
PL2358386T3 (pl) Zoptymalizowane szczepionki na grypę
GB0822001D0 (en) Vaccine
IL222228A0 (en) Hiv vaccine
IL212311A0 (en) Immunoenhancer-linked oligomeric hiv vaccines
EP2588211A4 (en) EPS TRIMER-IMMUNOGENIC
GB201006165D0 (en) Vaccine
GB0810710D0 (en) Vaccine
GB0918679D0 (en) Influenza vaccine
ZA201100962B (en) Influenza vaccines
GB0816284D0 (en) Vaccine
IL216102A0 (en) Combined measles-malaria vaccine
GB0816447D0 (en) Vaccine
GB201000522D0 (en) Vaccine
EP2424879A4 (en) INFLUENZA VACCINE
IL217194A0 (en) Vaccine
EP2240199A4 (en) INFLUENZA VACCINES
ZA201107971B (en) Combined measles-malaria vaccine
GB0914545D0 (en) Vaccine
GB0810215D0 (en) Vaccine
GB0809781D0 (en) Vaccine
GB0810914D0 (en) Vaccine